Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

Participants with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drugs.

All according to contraindications in the label especially:
* Participants with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections.
* Participants with moderate or severe heart failure (NYHA class III/IV).
* Participants with a history of hypersensitivity to infliximab or to other murine proteins, or to any of the excipients.

Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)